Dr. Nicolas André is a pediatric oncologist in the Department of Hematology & Pediatric Oncology in the “Hôpital pour Enfants de La Timone” in Marseille, France, where he is in charge of the pediatric oncology early clinical trial unit.
He is also a member of the CRO2-UMR INSERM 911- (Centre de Recherche en Oncologie Biologique et Oncopharmacologie) in Marseille.
He is the current chair of the SFCE pharmacology group.
He gained his medical degree in 2002 and a doctoral degree in 2003. He is the former president of the “Société Francophone de Recherche en Pédiatrie”.
Currently, his research interests and topics include pediatric brain tumors, pediatric rare tumors and pharmacology (new anticancer agents, metronomic chemotherapy). His has developed over the years an international expertise in metronomic chemotherapy has given lectures on metronomics worldwide.
The use of metronomic chemotherapy in "his" own patients has convinced him that this tool could be valuable for children in developing countries. He then launched Metronomics Global Health Initiative as the structure that could promote the development of metronomics with the highest standards and pave the way for new global strategies to fight cancer in developing countries.
He is the author of over 120 peer reviewed publications and book chapters.
Rajendra Achyut Badwe is currently the Director of Tata Memorial Centre. A surgical oncologist by specialty, he has been honoured by the Government of India, in 2013, with the Padma Shri, the fourth highest civilian award, for his contributions to the field of medicine.
Dr. Badwe is considered by many as an expert in oncology; his opinions are reportedly considered for devising cancer care strategies, disease management and research protocols worldwide. He is credited with pioneering research in breast cancer treatment, which is his specialty.
Dr. Badwe initiated and implemented the Clinical Research Secretariat (CRS) for the first time in India. He was also behind the establishment of the Department of Atomic Energy (DAE) Clinical Trials Centres for multi centre clinical trials. His mammoth research covering 1000 breast cancer patients in India had a reported effect in reducing breast cancer deaths by 25 per cent.
Michael Baum qualified in medicine at Birmingham University medical school in 1960. He held chairs of surgery at Kings College London 1980-1990, the Institute of Cancer Research 1990- 1995 and University College London 1995 -2001. In the past he has been President of the British Oncology Association, the European Breast cancer conference and chairman of the psychosocial committee of the National Cancer Research Institute. He has been awarded the William McGuire prize at San Antonio Texas, the Charles Gross prize in France, the St Gallen prize in Switzerland, the gold medal of the International College of surgeons for his research into the treatment of breast cancer and most recently the gold medal for therapeutics from the worshipful society of apothecaries in London. He was one of the first to challenge the doctrine of radical mastectomy and lead the first trial that demonstrated that tamoxifen could increase cure rates for breast cancer victims. He was also the first to describe psychometric instruments to measure quality of life in cancer sufferers. Most recently he has lead the first trial to demonstrate that one shot of intra-operative radiotherapy could replace 6 weeks post-operative treatment in selected cases.
On retiring as a professor of surgery at University College London, he has spent the rest of his career teaching and promoting “Medical Humanities” including fine art, literature and philosophy. His recently published his memoirs “Breast Beating: One man’s odyssey in the search for an understanding of breast cancer, the meaning of life and other simple questions” http://www.anshan.co.uk/pages/breastReview.html
His first novel “The third Tablet of the Holy Covenant” was published in November 2013. http://www.troubador.co.uk/book_info.asp?bookid=2383.
He will be launching his new book, “The Scepticaemic Surgeon”, published by Nova, NYC, on this crossing.
Married to Judy, three children, and 9 grandchildren. Other interests include painting, the history of art, philosophy of science, theatre, modern literature and the history of modern and ancient states of Israel.
Dr. Booth studied medicine at Queen’s University and completed postgraduate training in Internal Medicine at the University of Toronto. He completed his clinical training in Medical Oncology at the Princess Margaret Hospital. He subsequently spent two years as a research fellow with the NCIC Clinical Trials Group at Queen’s University Cancer Research Institute. Dr. Booth is a Medical Oncologist and Clinician-Scientist at Kingston General Hospital and an Associate Professor at Queen’s University. He holds the Canada Research Chair in Population Cancer Care. In his clinical practice he provides care to patients with gastrointestinal and genitourinary cancers. Dr. Booth has an active program in population-based cancer care and outcomes research. The focus of his research program is to evaluate the effectiveness of new therapies in the general population and the quality of care delivered to patients in routine clinical practice. In 2016 he will spend a sabbatical at the Regional Cancer Centre in Thiruvananthapuram, Kerala. Dr. Booth is also the Study Co-Chair of NCIC CTG CO21, an international randomized trial evaluating the role of exercise in patients with early stage colon cancer.
Professor of Radiation Oncology at the University of Liverpool; previously Professor of Clinical Oncology at the Institute of Cancer Research and the Royal Marsden Hospital in London. He is a leading international expert in neuro-oncology and thoracic oncology with a particular expertise in evaluation and implementation of new technology.
As an acknowledged national and international expert he served as the President of the European Association of Neuro-oncology (EANO), Chairman of the NCRI Brain Tumour Clinical Studies Group and as the President of The European Society of Therapeutic Radiation Oncology (ESTRO), a leading position in European radiotherapy. He has been elected an honorary member of a number of national radiation oncology societies and a founding Fellow of European Academy of Cancer Sciences.
He published benchmark studies of technical aspects and clinical outcome of stereotactic radiotherapy and key studies of late toxicity of cranial irradiation. Has been involved in the evaluation of chemotherapy and radiotherapy in glial tumours including initial studies of Temozolomide. In the last decade the principal focus has been on lung cancer, developing and testing novel technologies including motion management techniques and high precision irradiation.
Throughout his career he had a deep interest in improving methods of care and follow-up of cancer patients with studies resulting in changes to clinical practice. He is involved in evaluation of novel technologies in clinical setting through systematic reviews and meta-analyses, which have not infrequently generated heated debates. Authored and coauthored more than 250 peer-reviewed articles, editorials and book chapters.
Dr. David Collingridge has been Editor-in-Chief of The Lancet Oncology since March 2002, and is also the Publishing Director for The Lancet’s Specialty Journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK. Dr Collingridge has published numerous peer-review articles, editorials, opinion pieces, and news reports, and has co-authored a text book on radiobiology. He currently also holds the position of Clinical Associate Professor of Radiation Medicine at Hofstra North Shore-LIJ School of Medicine, Lake Success, NY.
As of December 1, 2014, Professor Fabien Calvo took the position of Chief Scientific Officer for Cancer Core Europe at Gustave Roussy Cancer Campus Grand Paris.
Fabien Calvo, MD PhD, is currently Professor of Pharmacology at University of Paris-Denis Diderot Medical School and was previously chief of clinical research department at Saint Louis Hospital in Paris. He is specialized in the field of genomics and the biology of metastatic disease, translational research, preclinical pharmacology and early clinical trials in hematology and oncology.
His role as Cancer Core Europe Chief Scientific Officer is to organize and coordinate medical research and scientific activities for this new European network, specifically working closely with the co-chairs, the Steering Group and the other scientific officers involved. Fabien Calvo also assist the consortium in developing a global vision and planning and delivering the implementation of the strategy.
From April 2007 to September 2014, Fabien Calvo was Deputy Director General of the National Cancer Institute of France (INCa), in charge of Research and Innovation Programs. Fabien Calvo was also during this period the director of the Cancer Multi-Organization Institute of the National Alliance for Life Sciences and Health (Aviesan), which includes INSERM, CNRS, CEA, INRA, INRIA, IRD, Pasteur Institute, Universities and University hospitals. He also launched with the USA, Canada, UK and Germany, the International Cancer Genome Consortium in 2008 (for which he chairs Scientific Planning Committee) and the Global Alliance for Genomics and Health. He was previously a resident and senior registrar of Paris Hospitals, National Cancer Institute in Bethesda (NIH / NCI / DCT, USA).
From 1995, he was the Director and founder of the Inserm Clinical Investigation Center at the Saint- Louis Hospital. He was also the Director of Inserm Unit 716, working on the identification of new molecular targets for cancer treatment. He is a board member of the post-graduate school “fundamental basis of carcinogenesis”.
Fabien Calvo worked as a coordinator of the cancer mission for the Director of the Research and Innovation department, Ministry of Research and Higher Education (2006-2007).
Alberto Costa MD is Scientific Director and CEO of the European School of Oncology (ESO), established in Milan in 1982 as a private non profit educational organisation in cancer medicine (www.eso.net). He is also Editor of the School’s magazine, CancerWorld, available online at www.cancerworld.org
Costa was trained in Milan in cancer surgery and particularly in breast cancer management. He is Breast Unit Clinical Director at Multimedica, Milan, Italy, and Chair of the Advisory Board of the Canton Ticino Breast Unit, Lugano, Switzerland. Both of these units are certified by EUSOMA (European Society of Mastology). He is one of the editors of the journal The Breast and a member of the editorial boards of some leading cancer publications including the European Journal of Cancer and Nature Reviews Clinical Oncology.
Previously he has served as Secretary General of the European Organisation for the Research and Treatment of Cancer (EORTC) and Federation of European Cancer Societies (FECS). He was a member of the European Commission's Europe Against Cancer programme and currently seats in the Commission’s Committee of Cancer Experts representing ECCO (the European CanCer Organization, Brussels) of which he is a Board member. At national level he has played a key role in the creation of the Italian School of Senology and of the European Institute of Oncology in Milan.
Internationally recognized for his work for the advancement of breast cancer management and the recipient of several awards, Dr Costa is also renowned for his innovative ideas in scientific communication and educational development, specifically the training of doctors. As Director of the European School of Oncology, his work has helped elevate the standards of training and medical care in the field of cancer globally. He has actively encouraged the establishment of collaborative relationships with international organizations and institutes thus promoting the essential sharing of knowledge and experience everywhere for the widest benefit of cancer patients.
Ronald A. DePinho, M.D., is President of The University of Texas MD Anderson Cancer Center in Houston. His research program has focused on the molecular underpinnings of cancer, aging and degenerative disorders and the translation of such knowledge into clinical advances. Dr. DePinho’s independent scientific career began at the Albert Einstein College of Medicine, where he was the Feinberg Senior Faculty Scholar in Cancer Research. He then joined the Department of Medical Oncology at the Dana-Farber Cancer Institute and the Department of Medicine and Genetics at the Harvard Medical School. He was the founding Director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute anda Professor of Medicine and Genetics at Harvard Medical School. Dr. DePinho has held numerous board positions and received many honors and awards. He is a newly inducted fellow of the American Association for Cancer Research Academyand a member of the National Academy of Sciences. He also is a founder of a number of biopharmaceutical companies focused on cancer therapy and diagnostics.
Dr. Fojo was born in Havana, Cuba, moved to the United States with his family in 1960, and became a U.S. citizen in 1970. He received his MD and PhD from the University of Miami. He completed 3 years of training in Internal Medicine at Washington University/Barnes Hospital in St. Louis, and after a year as Chief Resident moved to the National Cancer Institute as a Clinical Associate in the Medicine Branch. After 3 years with Drs. Ira Pastan and Michael Gottesman, he assumed the position of Senior Investigator in the intramural program of the NCI, a position he held until August 2015 when he moved to Columbia University. For the years he was Director of the Medical Oncology Fellowship Program one of the largest in the United States. He is currently a Professor of Medicine at Columbia University in the Division of Hematology / Oncology, Head of the Neuorendocrine Program and Co-Director of the Adrenal Center at Columbia University / New York Presbyterian. His research interests include: (1) The biology, molecular biology and therapy of neuroendocrine tumors, adrenocortical cancers and pheochomocytomas with an emphasis on the development of better therapies; (2) Microtubule-targeting agents - how they work and how to better use them; (3) Drug resistance - understanding basic mechanisms of resistance and how to improve therapies by overcoming such mechanisms; (4) The conduct of clinical trials especially as they relate to drug approvals and drug costs; and (5) Novel ways to analyze clinical data to better understand outcomes and to mine such data for basic insights.
Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).
In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.
Varsha Gandhi, Ph.D. received her doctorate degree in biochemistry from Delhi University in India. After a brief period at Rice University, she joined MD Anderson Cancer Center as a postdoctoral fellow and was promoted to Assistant, Associate, and full professor. Currently, she is a Rebecca Meyer Brown & Joseph Mellinger Brown Chair in Basic Science Research in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. She is ad interim Chair for this department and also serves as Director of the Center for Targeted Therapy.
Dr. Gandhi's research focus is in the development of therapeutics for hematological malignancies. She uses biologic, biochemical, and molecular approaches to understand the metabolism and mechanism of action of different groups of chemotherapeutic agents. Based on mechanism of action of novel agents and biology and pathophysiology of the disease, her group tests these drugs in hematological malignancies. Currently, her group is working on several targets such as Met receptor tyrosine kinase in myeloma, Bcl-2 antagonists in leukemias, inhibitors of Pim kinase, Bruton’s tyrosine kinase as well as PI3 kinase in heme malignancies, and novel small molecule inducers of apoptosis. Her research is translational in nature and her group validates the laboratory-tested hypotheses in the clinic using target tumor tissues. Based on mechanisms of action of chemotherapeutic agents, they also test and develop novel combination strategies. Dr. Gandhi has published more than 250 articles and serves on the editorial board of several journals including Clinical Cancer Research, Leukemia, and Leukemia and Lymphoma.
She designed and developed a new graduate program “Experimental Therapeutics”andhas been serving as a Director of this program, Experimental Therapeutics Academic Program (ETAP). She has supervised and trained more than a dozen graduate students and several postdoctoral fellows in her laboratory and plays a major role in the GSBS. Within the department, she also initiated and established a mentoring program for trainees and junior faculty.
Dr. Gandhi has several investigator-initiated peer-reviewed grant support. In addition, she has grant funding from Leukemia and Lymphoma society, The V Foundation, and CLL European Alliance and sponsored research agreements from industry.
Dr. Gandhi has received several awards. These include MD Anderson Faculty Scholar Award, Gerald P. Bodey Award for Excellence in Education, MD Anderson Distinguished Research Faculty Mentor Award, Ruby E. Rutherford Distinguished Professorship, The University of Texas System Regents' Outstanding Teaching Award, and Chamberlain Postdoctoral Mentor Award. She is also a Fellow of the American Association for the Advancement of Science (AAAS).
Mary Gospodarowicz is Professor of Radiation Oncology at the University of Toronto, the Medical Director of the Princess Margaret Cancer Centre at the University Health Network, and the Regional Vice President of Cancer Care Ontario. She is past Chair of Radiation Oncology at the University of Toronto. She holds specialty certifications in internal medicine, radiation oncology, and medical oncology and her clinical practice involves lymphomas and genitourinary cancers. Her research focused on clinical trials evaluating radiation therapy, image-guided precision radiotherapy, and cancer survivorship. Her current interests include global cancer control, global access to radiotherapy, and quality cancer care.
Professor Gospodarowicz is the Immediate Past-President of the Union for International Cancer Control (UICC). She proudly participates in the work of the Global Task Force on Cancer Care and Control of Harvard Global Equity Initiative, the UICC’s Global Task Force on Radiotherapy for Cancer Control, and the HGEI-Lancet Commission on Global Access to Pain Control & Palliative Care.
She is the Associate Editor of Journal of Global Oncology and a long standing member of ASCO, a Fellow of the American Society in Radiation Oncology (ASTRO), Honorary Fellow of the Royal College of Radiologists in the United Kingdom, and Honorary Fellow of the Faculty of Radiologists in the Royal College of Surgeons of Ireland. She is an honorary member of the European Society of Therapeutic Radiology and Oncology (ESTRO), the Scientific Association of Swiss Radiation Oncology (SASRO), and the German Society for Radio-oncology (DEGRO). She is a recipient of numerous awards including the Gordon Richards Lectureship from the Canadian Association of Radiation Oncologists, the May Cohen Award for Women Mentors from the Canadian Medical Association, the Janeway Medal from the American Radium Society,the ESTRO Lifetime Achievement Award, and the ASTRO Gold Medal. In July 2015, she was appointed Officer of the Order of Canada.
Professor Matti Kaarlo Hakama held the positions of Professor of Epidemiology at the University of Tampere, Finland, from 1975–2003. He was also the Director of the Mass Screening Registry, Finnish Cancer Registry, 1968–2004 and the Director of Tampere School of Public Health, Finland, 1999–2001.
Prof Hakama was born in Oulu, Finland on 9 November 1939.
ScD, 1970, University of Helsinki.
MSc, 1966, University of Minnesota
He has played a key role in several international activities in WHO, UICC and Council of Europe. He has supervised more than 50 doctoral dissertations including from 20 Indian epidemiologists. Prof Hakama has published more than 400 scientific papers on cancer registration screening, and epidemiology.
Dr. Daniel F. Hayes is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, where he is the Stuart B. Padnos Professor of Breast Cancer Research.
Dr. Hayes received bachelor’s, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Health Science Center/Parkland Memorial Hospital from 1979 to 1982. After a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI) from 1982 to 1985, he remained on faculty and was the Medical Director of the Breast Evaluation Center at DFCI from 19912-1996. He subsequently became the Director of the Breast Cancer Program at Georgetown University’s Lombardi Cancer Center from 1996 to 2001, when he moved to the University of Michigan.
Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers related to breast cancer. His work has been particularly focused on development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and pharmacogenomic markers that have prognostic and/or predictive value in the treatment of breast cancer. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility.
Currently, he is chair of the SWOG Breast Cancer Translational Medicine Committee, and he is past chair of the Correlative Sciences Committee of the North American Breast Cancer Group. He was an inaugural member of the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee, which he co-chaired for the last decade. Dr. Hayes served on the 2011 to 2014 American Society of Clinical Oncology (ASCO) Board of Directors, and in 2015 he was elected to serve a three-year term as President of ASCO. He is a Fellow of ASCO, and he serves on the Susan G. Komen for the Cure Scientific Advisory Council as a Komen Scholar. He is a member of the Association of American Physicians and of the American Clinical and Climatologic Association, and he was the inaugural recipient of the ASCO Gianni Bonadonna Award for research and mentoring in breast cancer.
Dr. Hayes lives in Ann Arbor, Michigan, with his wife, Jane.
Dr. David Jaffray graduated from the University of Alberta, Edmonton, Alberta, Canada with a B.Sc. in Physics (Hons.) in 1988 and completed his Ph.D. in the Department of Medical Biophysics at the University of Western Ontario, London, Ontario in 1994. Following graduation, he took a position as Staff Physicist in the Department of Radiation Oncology at William Beaumont Hospital, Royal Oak, Michigan where he instigated a direction of research that garnered funding from the NIH and from congressionally-directed funding programs. Dr. Jaffray became a Board Certified Medical Physicist (ABMP – Radiation Oncology) in 1999. In 2002, Dr. Jaffray joined the Princess Margaret Cancer Centre in Toronto, Ontario as Head of Radiation Physics and a Senior Scientist within the Ontario Cancer Institute. David holds the Fidani Chair in Radiation Physics and is a principal in the STTARR Innovation Centre and Guided Therapeutics (GTx) Group of the University Health Network. He is the Director of the recently established Institute of Health Technology Development at the University Health Network (TECHNA). In October 2015, he is appointed as the Executive Vice-President, Technology and Innovation at the University Health Network; he oversees Medical Physics, Biomedical Engineering and Information Technology across UHN.
He is appointed as a Professor in the Departments of Radiation Oncology, Medical Biophysics, and Institute for Biomaterials and Biomedical Engineering at the University of Toronto. His primary area of research over the past 10 years has been in the development and application of image-guided radiation therapy. He has over 10 patents issued and several licensed, including, kilovoltage cone-beam computed tomography for image-guided radiation therapy. Dr. Jaffray has in excess of 200 peer-reviewed publications in the field, in excess of 300 invited lectures, and holds numerous peer-review and industry sponsored research grants.
He sits on numerous scientific and research boards and has contributed to the NIH and CIHR grant review process for several years. He is a member at large of the Science Council of the AAPM and has an active teaching role in workshops and annual meeting of the American Society of Therapeutic Radiation Oncology (ASTRO). He has an active interest in commercialization and led the development of a variety of commercial products including software and hardware for QA and the development of small animal irradiator systems for basic research. He has successfully supervised over 40 graduate students and fellows. Dr. Jaffray has won each of the major prizes in the field of the medical physics, including, the Sylvia Sorkin-Greenfield Award, The Farrington Daniels Award, and the Sylvia Fedoruk Award. In 2004, Dr. Jaffray was identified as one of Canada’s Top 40 Under 40 and was recognized by The University of Western Ontario with their Young Alumni.Award in 2004. His current research interests focus on the development of novel approaches of targeting Radiation Therapy, the development of image – guided therapies for Cancer and translating these advances to clinical practice.
Bakulesh Khamar is Executive Director-Research at Cadila Pharmaceuticals Ltd, India since 1996. At Cadila Pharmaceuticals the focus is on to develop innovative products while continuing development of generic products. Pursuing the philosophy of Cadila, he is responsible for bringing innovations; he is also leading the team towards analyzing information that leads to development of a product with unique features.Some of the innovative products under various stages of development in cancer management include:
Innovative products under various stages of development in other areas include:
Some of the unique products developed include:
Besides monitoring research activities in Cadila Pharmaceuticals, he is a leading eye specialist and still actively practicing ophthalmology. He has been an active teacher and researcher and has held positions as Professor of Ophthalmology at N.H.L. Municipal Medical College, Ahmedabad, and visiting faculty at Shankara Netralaya, Chennai and University of California-Berkeley.
Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. Vijay Kuchroo is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He was just named the Director of the newly formed Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases - particularly the role of co-stimulation - the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction. His laboratory has made several transgenic mice that serve as animal models for human multiple sclerosis. Dr. Kuchroo first described the inhibitory receptor TIM-3, which is being exploited as a target for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which has been shown to induce multiple different autoimmune diseases in humans. He has published over 325 original research papers in the filed of Immunology and a paper describing development of Th17 authored by Dr. Kuchroo has been one of the highest cited papers in Immunology.
Dr. Kuchroo came to the United States in 1985 and was at the National Institutes of Health, Bethesda as Fogarty International Fellow for a year before joining the department of pathology at Harvard Medical School as a research fellow. He later joined the Center for Neurologic Diseases at Brigham and Women's Hospital as a faculty member in 1992.
He obtained his degree in Veterinary Medicine from the College of veterinary medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane (Australia) where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly lecturer in 2014 and obtained Nobel Laureate Peter Doherty lecture/prize in 2014.
Dr. Kuchroo has 25 patents and has founded 6 different biotech companies. He also serves on the scientific advisory boards of a number of big pharmaceutical companies including Pfizer, Novartis, Sanofi/Genzyme and Glaxo-Smith-Klein (GSK).
Douglas Lowy is acting director of the National Cancer Institute and Chief of the intramural Laboratory of Cellular Oncology in the Center for Cancer Research at the NCI. He received his medical degree from New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale University. His research includes papillomaviruses and the regulation of normal and neoplastic growth. The papillomavirus research is carried out in close collaboration with John Schiller, with whom he has co-authored more than 100 papers over the past 25 years. In the 1980s, he studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. More recently, he has worked on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that have been approved by the US Food and Drug Administration and many other countries. It is for this body of work that Drs. Lowy and Schiller received the 2007 Federal Employee of the Year Award from the Partnership for Public Service, the 2007 Dorothy P. Landon-American Association for Cancer Research Prize for Translational Cancer Research, the Sabin Gold Medal in 2011, and the National Medal of Technology and Innovation from President Obama in 2014. Dr. Lowy also received the 2007 Medal of Honor for basic research from the American Cancer Society. He is listed by the Institute for Scientific Information as one of the most highly cited authors in microbiology, and is a member of the National Academy of Sciences and the Institute of Medicine of the NAS.
Professor Indraneel Mittra holds the Dr. Ernest Borges Chair in Translational Research and is Professor Emeritus, Department of Surgical Oncology at the Tata Memorial Centre, Mumbai. Earlier, Professor Mittra was Professor of Surgery and Chief of the Surgical Breast Service and Head, Division of Laboratory Medicine at TMC. Professor Mittra received his medical degree from the University of Delhi in 1965 and was awarded the Fellowship to the Royal College of Surgeons of England in 1971. He obtained his PhD degree in cancer biology from the University of London and trained as a post doctoral research fellow under the Nobel Laureate, Dr. Renato Dulbecco at the Imperial Cancer Research Fund Laboratories, London.
Professor Mittra's interests are wide ranging and encompass clinical, laboratory as well as public health research in cancer. He was the founder Principal Investigator of a major NCI funded randomized trial of early detection of breast and cervical cancer using low cost technology approaches. The study has established that visual inspection of the cervix using 4% acetic acid reduces mortality from cervical cancer by 31%. The breast cancer part of the study will be concluded in 2016. Professor Mittra’s laboratory research has led to the discovery that circulating nucleic acids are biologically active molecules and cause damage to DNA of healthy cells by integrating into their genomes. These findings have far-reaching implications for multitude of human disorders including ageing and cancer.
Professor Mittra is / has been on the Editorial / Advisory Board of British Medical Journal, Lancet Oncology, Nature Reviews Clinical Oncology, British Journal of Cancer, European Journal of Cancer, International Journal of Surgery, Critical Reviews in Hematology/Oncology, and the Journal of Biosciences. Professor Mittra has authored nearly 100 publications in the field of cancer and is a Fellow of the Indian National Science Academy and Indian Academy of Sciences.
Dr. Matthew Meyerson is Professor of Pathology at Dana-Farber Cancer Institute and Harvard Medical School and Institute Member of the Broad Institute of Harvard and MIT. The focus of his laboratory is to use genomic approaches to uncover the causes of human disease, particularly lung cancer. For The Cancer Genome Atlas, or TCGA, project of the NIH, Dr. Meyerson serves as principal investigator of a Genome Characterization Center and is co-chair of TCGA’s lung cancer disease working group.
The Meyerson laboratory has pioneered numerous computational and experimental approaches in cancer genomics and has made many major discoveries in human lung cancer, including alterations of the EGFR, BRAF, U2AF1, RBM10, NKX2-1 and TERT genes in lung adenocarcinoma and mutations of FGFR2, FGFR3 and DDR2 and amplification of SOX2 in lung squamous cell carcinoma (meyersonlab.dana-farber.org). The discovery by the Meyerson group and others of activating mutations in EGFR that dictate patient response to EGFR inhibitors helped establish the foundation for today’s precision medicine approach to cancer care.
Dr. Meyerson is the recipient of the Paul Marks Prize in Cancer Research and a Research Professorship from the American Cancer Society.
Aruna Ramachandran received her PhD from the National Institute of Immunology, New Delhi, and is a research scientist in the Meyerson laboratory. Her scientific interests lie in understanding the molecular mechanisms of cancer. She contributes to the laboratory’s research programs, communications and broader scientific strategy.
Dr. Amit Oza is a Senior Staff Physician and Professor of Medicine at Princess Margaret Cancer Centre, Toronto. He is Interim Head of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre and Director of Princess Margaret Cancer Centre‘s Cancer Clinical Research and Drug Development programs. He graduated from St. Bartholomew's Hospital, University of London (UK) and completed his internal medicine and medical oncology training in UK. He completed Clinical Research Fellowships at St.Bartholomew's Hospital/Imperial Cancer Research Fund, London (UK), PMH, Toronto and at the Netherlands Cancer Institute, Amsterdam. He is a Fellow of the Royal College of Physicians of London and Canada.
Dr. Oza has been the PI and program scientific lead for the Princess Margaret Hospital Consortium over the last nine years. He is Co-Chair of NCI Investigational Drug as well as the Gynecologic Cancer Steering Committees. He is CEO of Ozmosis Research, a not for profit social enterprise clinical research organization. He has been an active PI and co-investigator in phase I, II, and III trials for gynecological cancer. His research interests are focused towards the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research, which are developed in close relationship with scientists and pathologists at Ontario Cancer Institute/Princess Margaret Cancer Centre. He is the principal and co-author of >200 publications in major peer-reviewed journals such as New England Journal of Medicine, Lancet Oncology, Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.
Professor Julian Peto DSc FMedSci holds the Cancer Research UK Chair of Epidemiology at the London School of Hygiene & Tropical Medicine. After studying mathematics at Oxford and statistics at Imperial College in London he worked for five years as a statistician at Edinburgh University, the Institute of Psychiatry and the Medical Research Council's T.B. Unit. He returned to Oxford in 1974 to join the ICRF Cancer Epidemiology and Clinical Trials Unit headed by Sir Richard Doll. In 1983 he was appointed Chairman of the Section of Epidemiology at the Institute of Cancer Research in London. He moved to the London School of Hygiene and Tropical Medicine in 2004.
Together with Bruce Ponder, Doug Easton and Mike Stratton he initiated the work at the Institute of Cancer Research that led to the discovery of BRCA2 and subsequent GWAS studies on less penetrant susceptibility loci. His work on asbestos began 40 years ago with dose-response models for lung cancer and mesothelioma to regulate working conditions when asbestos was still being used in Britain. He is now studying asbestos lung burden to assess the extent of current occupational and environmental asbestos exposure from the asbestos still present in many buildings. His other work has included the natural history of human papillomavirus (HPV) infection and cervical cancer, particularly in relation to screening, clinical trials on various cancers, and epidemiological studies on occupational carcinogens, childhood cancers, oral contraceptives and breast cancer. He leads the VIDAL (Vitamin D and Longevity) Trial, which began recruitment in 2013.
Akhilesh Pandey, is a Professor at the McKusick-Nathans Institute of Genetic Medicine and the Departments of Biological Chemistry, Oncology and Pathology at the Johns Hopkins University School of Medicine. He is also the Founder and Director of the Institute of Bioinformatics, a non-profit research institute in Bangalore, India. He obtained his medical degree from Armed Forces Medical College in Pune, India and completed his residency in Pathology at the Brigham and Women's Hospital at Harvard Medical School in Boston. He obtained his Ph.D. in the laboratory of Vishva Dixit at the University of Michigan, Ann Arbor in 1995 and carried out his Postdoctoral work in the laboratory of Harvey Lodish at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology. Subsequently, he was a Visiting Scientist with Matthias Mann at the University of Southern Denmark for three years before joining Johns Hopkins University School of Medicine in 2002. During his tenure in Denmark, he developed the SILAC method for quantitative proteomics, which is now a gold standard for accurate quantitation of proteins and post-translational modifications. He has pioneered methods for quantitative proteomics and for analysis of post-translational modifications by mass spectrometry. Dr. Pandey’s laboratory is taking a systems biology approach by combining many 'Omics' technologies to characterize signaling pathways and to discover biomarkers in cancer. Recent work from his laboratory has led to detailed elucidation of PI3-Kinase signaling pathway and discovery of several tyrosine kinases as novel therapeutic targets in breast cancer. He has published over 300 papers and currently serves as an Editorial Board member of Molecular and Cellular Proteomics, Journal of Proteome Research, Proteomics, Clinical Proteomics, Journal of Translational Medicine and DNA Research and as an Associate Editor of Journal of Proteomics.
Sen Pathak, is a geneticist and Professor of Cell Biology and Laboratory Medicine at The University of Texas M.D. Anderson Cancer Center in Houston; Professor, Genetics Program at The Graduate School of Biomedical Sciences, The Health Science Center and at The School of Health Professions, Houston; Professor of Medicine at Baylor College of Medicine; Senior Scientist (adjunct) in the Department of Genetics at Southwest Foundation for Biomedical Research, San Antonio, Texas, USA. He is also a Visiting Professor of Genetics at The University of Sao Paolo and currently a Lifetime Emeritus Professor of Cancer Biology and a Distinguished Research Professor of Genetics at The University of Texas M.D. Anderson Cancer Center. He is an internationally recognized scientist for his pioneering research work first on Mammalian Population Cytogenetics and lately on human and other mammalian Cancer Genetics.
By using Giemsa (G-) and C- banding techniques, Pathak was the first to cytogenetically identify three hybrid animals between two species of the Climbing Rat, genus Tylomys. These hybrids were identified from a group of 11 animals that were given to him for their cytogenetic analyses as his first project at M.D. Anderson Cancer Center. Pathak’s another significant contribution is of bringing awareness to researchers about the cancer cell line contamination and their authentication. Based on a open letter written to the Secretary of USHHS in 2007 by 17 eminent cancer researchers including Pathak from US and UK regarding the problem of cell line contamination and misidentification, guidelines for the authentication of cell lines are now being seriously considered by many Funding agencies, Editorial Board of High Impact journals, Cancer Centers and Research Institutes. Finally, Dr. Pathak is a world expert on the identification of various mammalian interspecies and intraspecies including human cell line contamination.
Dr Pathak has trained more than 30 doctoral, postdoctoral and visiting scholars from around the world, and this list is increasing. Pathak has received numerous other honors and awards. Dr. Pathak has been serving as Reviewer, Member of the Editorial Board, Co-Editor and Associate Editor of more than 50 National and International Journals including – Science, Nature, Proceeding of the National Academy of Sciences, USA, Cell and many others. He has published more than 358 peer-reviewed articles, contributed to more than 20 books, chapters and review articles, and has launched the careers of more than two dozens of basic and translational cancer research scientists.
Vinay Prasad MD MPH is a practicing hematologist-oncologist and Assistant Professor of Medicine at the Knight Cancer Institute and the Oregon Health and Sciences University. He is nationally known for his research on oncology drugs, cost, health policy, evidence-based medicine, bias, public health, preventive medicine, and medical reversal.
Dr. Prasad's work has demonstrated that many medical practices, promoted and advocated for decades, are ultimately shown not to work. These reversals typically occur when we adopt new therapies based on incomplete or inadequate studies. Dr. Prasad has also demonstrated that the high cost of cancer drugs is not explained by rational factors, that media coverage of medical articles preferentially covers lower levels of evidence, that industry sponsored randomized trials have substantial bias, and that many current medical practices have no convincing proof of efficacy (e.g. IVC filters). Dr. Prasad and Dr. Adam Cifu (University of Chicago) have a forthcoming book entitled Ending Medical Reversal: Improving Outcomes, Saving Lives, which will debut in November 2015.
Dr. Prasad is a graduate of the University of Chicago Pritzker School of Medicine, where he was awarded the Chairman's Award in Internal Medicine. He is also a graduate of Johns Hopkins Bloomberg School of Public Health and completed his undergraduate at Michigan State University, where he was commencement speaker for the College of Arts & Letters. Dr Prasad trained in general internal medicine at Northwestern University in Chicago, where he received the Gerald Grumet award for best resident teacher, and completed his fellowship in Hematology and Oncology in the joint program between National Cancer Institute, and National Heart, Lung and Blood Institute both at the US National Institutes of Health.
Dr. Prasad is the author of more than 100 peer-reviewed articles in academic journals, including the New England Journal of Medicine and the Journal of the American Medical Association. His work has been widely covered by news outlets including the New York Times, USA Today, the Wall Street Journal, NPR and Forbes. When not working, Dr. Prasad enjoys cycling, reading and binge watching television.
Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. He is on staff at Harvard TH Chan School of Public Health, faculty at University College London, and Prof. Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. His specialty is using computer simulation and stochastic techniques to model cancer growth and metastatic development. He is a key investigator of a project proposing a revolutionary theory that early relapses in breast cancer result from transient systemic inflammation after primary surgery and can be dramatically reduced by using a perioperative NSAID. Diagnosed with stage IIIc colon cancer in 1994, he used a low-dose long-term 5FU infusional therapy. After discussing this therapy with Folkman and Tim Browder in 1996, it led to an investigation at the Folkman laboratory and the classic Browder et al paper on metronomic chemotherapy. Retsky is Editor of a Springer Publishing Company book on breast cancer to be issued later in 2016 and is Editor-in-Chief of the Journal of Bioequivalence and Bioavailability. He is a founder and on the Board of Directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has two patents pending for treatment of early stage cancer. As a result of the 2001 attacks on The World Trade Center he used his physics background to invent and patent an orbiting “star wars” device to defend against ballistic missiles.
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco Helen Diller Family Comprehensive
Cancer Center San Francisco, CA
Dr. Rugo is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, where she directs Breast Cancer and Clinical Trial Education. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care.
She is an investigator in the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. She is 1 of 3 recipients of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials. Dr. Rugo is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of breast cancer and supportive care-related topics.
With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. In addition, she completed a 2-year postdoctoral fellowship in immunology at Stanford University. She received the Cancer Care Physician of the Year Award in 2010.
Trained in Clinical and Radiation Oncology at TMH & Royal Marsden Hospital, London, he joined as faculty in TMH 1996 and led the Breast Cancer & Brain Tumour Radiotherapy & Cancer Genetics group before becoming Director ACTREC in 2005. He established the 1st Indian comprehensive Cancer Genetics Unit –Genetics Clinic in TMH and Genetics Lab (Sarin Lab) in ACTREC and the ICMR Centre for Advanced Research in Cancer Genetics with 3600 hereditary cancer families.He is the lead investigator in the International Cancer Genome Consortium (ICGC) India oral cancer project and member of two International working groups of the ICGC. As Director ACTREC he helped establish state-of-the-art BMT, Neurosurgery and Hi-Precision Radiotherapy programme and promoted translational research with 40 new faculty including 10 new PIs. He serves on several apex national task forces and expert committees for cancer research and drafted the base paper for research for the Indian National Cancer Control Programme. He has several highly cited publications and has edited 2 books. He established the Journal of Cancer Research & Therapeutics as its executive editor, making it one of the leading indexed cancer journal from the developing world. He has served on the editorial board of leading cancer journals including Lancet Oncology, Molecular Oncology and Radiotherapy Oncology. His current research focuses on establishing the founder effect and age of recurrent germline mutations in Indian families with hereditary cancer syndromes and in functional genomics of novel genetic alteration identified in through genome sequencing of oral cancers in the ICGC project.
Dr Akshita Singh is an unique person, being a surgical oncologist specializing in breast cancer and at the same time training to be a scientist. She completed her surgical training at Tata Memorial Hospital and is currently pursuing a PhD at ACTREC. Prior to her PhD course, Akshita spent two and a half years in the Translational Research Laboratory working under Professor Indraneel Mittra where the work to be presented by her was conducted. Her work challenges the current dogma regarding cancer metastasis, and will provide new insights that may revolutionalize our thinking about cancer.
Dr. Ana M. Soto is a professor in the Department of Integrative Physiology and Pathobiology at Tufts University School of Medicine, in Boston, MA. For over three decades, Dr Soto’s research interests have centered on a) the control of cell proliferation by sex steroids, b) the developmental origins of adult disease, particularly the role of endocrine disruptors on carcinogenesis, reproduction and obesity, c) the role of stroma/epithelial interactions on organogenesis and carcinogenesis and d) the role of biomechanics on morphogenesis.
Dr. Soto also works on theoretical and epistemological issues arising from the study of complex biological phenomena. In this regard, in collaboration with Professor Carlos Sonnenschein, she co-authored a book entitled THE SOCIETY OF CELLS (Bios-Springer-Verlag, 1999), posited that the default state of cells in all organisms is proliferation, and proposed the Tissue Organization Field Theory of Carcinogenesis, in which cancer is viewed as development gone awry. As the incumbent Blaise Pascal Chair in Biology, she co-ordinates a multidisciplinary working group devoted to the elaboration of a theory of organisms.
Dr. Soto is the recipient of several awards, including the 2012 Gabbay Biotechnology & Medicine Award of Brandeis University, presented to her, Dr. Sonnenschein and Dr. Hunt as a result of their contributions to public health. She has been elected a member of the prestigious Collegium Ramazzini, Carpi, Italy in 2011, and was named the 2013 Blaise Pascal Chair in biology at the Ecole Normale Superieure in Paris, France.
Her research has been funded by the US National Science Foundation, the US-National Cancer Institute, the US EPA, the Susan G. Komen Foundation, the US-National Institute of Environmental Health Sciences, the Avon Foundation and the UK Medical Research Council.
Carlos Sonnenschein, MD is a Professor at Tufts University School of Medicine and corresponding member at the Centre Cavaillès, Ecole Normale Supérieure, Paris, France, as well as a Visiting Professor at the University of Ulster, UK. For over four decades, Dr. Sonnenschein’s research interests have centered on a) the control of cell proliferation by estrogens and androgens, b) the impact of endocrine disruptors on organogenesis and the reproductive function and c) carcinogenesis during early development and adult life and, specifically, on the role of stroma/epithelial interactions on rat and human mammary carcinogenesis.
At the beginning of the 1970s, Dr. Sonnenschein established and characterized the first estrogen-target cell lines that later on significantly impacted current understanding of the estrogenic control of these target cells and that of cells from multicellular organisms, at large. In the late 1980’s, Ana M. Soto and Sonnenschein identified estrogenic substances in plastics and developed two in vitro bioassays capable of reliably identify xenoestrogens and androgens agonists and antagonists (E-SCREEN and A-SCREEN, respectively) that are used worldwide to detect the presence of natural and man-made estrogenic and anti-androgenic compounds. Both researchers have served in national and international advisory panels that deal with diverse aspects of environmental sciences. Together with Patricia Hunt (Washington State University), Drs Sonnenschein and Soto shared the 2012 Jacoh Heskel Gabbay Price awarded by Brandeis University in recognition of their contributions in Medicine and Biotechnology.
In 1999, Drs Sonnenschein and Soto co-authored a book entitled THE SOCIETY OF CELLS (Bios-Springer-Verlag) in which they critically evaluated the status of research in the fields of control of cell proliferation and carcinogenesis. The major conclusions reached by their analysis in the book were that a) the default state of all cells in both unicellular and multicellular organisms is proliferation, and that b) sporadic cancers (over 95% of clinical cases) are anchored at the tissue level of biological organization. These are the core premises of their theory of carcinogenesis and metastases, i.e., the tissue organization field theory (TOFT). Based on evidence they and others have collected, the TOFT is increasingly accepted by the cancer research and secular communities as reflected in scholarly and lay publications.
During the last 10 years, the Sonnenschein/Soto laboratory has developed the only 3D model of the human breast that responds to the three mammotropic hormones. In addition, they also developed experimental models to study the biophysical determinants of morphogenesis. Dr. Sonnenschein has been posing candid questions on a number of basic notions in biology and suggesting provocative answers to them. He maintains an active traveling schedule to national and international destinations to give seminars and lectures at colleges, universities and research institutes in the US, Europe, Asia and Latin America.
Nikolas Stoecklein is currently a Professor for Experimental Surgical Oncology at the Heinrich-Heine University Düsseldorf (HHU), Germany. His major research interests are minimal residual disease and early systemic disease in cancer. Currently, his group focuses on CTCs as liquid biopsy, ultimately, to improve systemic cancer therapies. He pioneered Diagnostic Leukapheresis (DLA) for enhanced CTC detection and established workflows to analyze the rare CTCs comprehensively at single cell level. Nikolas is currently part of two European consortia (CTCTrap and CANCER-ID) that develop and validate liquid biopsy approaches in the clinical setting. Prior joining the HHU, Nikolas obtained post-doctoral training at the Institute of Immunology of the Ludwig-Maximilians-University Munich, Germany, in the group of Christoph Klein. He graduated from the University of Hamburg, Germany, in 1998 where he studied medicine.
Richard Sullivan is Professor of Cancer & Global Health at Kings College London (KCL), Director, Institute of Cancer Policy and Co-Director of King’s Conflict & Health Research Group. He is a member of the executive boards of King’s Health Partners Comprehensive Cancer Centre, the Centre for Global Health at King’s and the Union for International Cancer Control. He also holds Visiting Chairs at the Universidad Catolica, Santiago and Tata Memorial Centre.
Richard is past UK Director of the Council for Emerging National Security Affairs (CENSA) a national security think-tank where he specialised in counter-proliferation and the security implications of global health. Richard qualified in medicine, and trained in surgery (urology) gaining his PhD in cell signalling from University College London. He was clinical director of Cancer Research UK between 1999 and 2008. Following a period at the London School of Economics working on complex healthcare systems he moved to KCL in 2011.
Richard’s research programmes at KHP CCC focus on to areas: global cancer policy and conflict & health. In global cancer public policy the ICP works a on range of global policy research programmes, most recently Lancet Commission on Global Surgery 2030, Lancet Series on Women’s Equity, Health and Cancer and the Lancet Oncology Commission on Global Cancer Surgery.
Conflict & Research Group is carrying out a Lancet Commission into Civil-Military co-operation in Global Health, in addition to a wide variety of field studies including: basic package of health services in Afghanistan, armed violence reduction as public health measure, intelligence, security and global health, and health intelligence in the Syrian conflict. Richard has worked extensively in many conflict regions from the Balkans through to Afghanistan, Libya, Syria and DR Congo in both healthcare systems reconstruction and cancer control.
Dr. Ian Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD in London, England and his MD at University of Pennsylvania, Philadelphia, USA. His clinical research investigates methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of previous (mitoxantrone) and current (docetaxel) standard chemotherapy.
His laboratory research evaluates effects of the tumour microenvironment on outcome of cancer therapy. He is an editor of the Basic Science of Oncology textbook, now in its 5th edition that is used by trainees in all branches of oncology. Dr. Tannock was a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) from 2001-2004. He received the alumnus award from M.D. Anderson Hospital, Houston, USA (1989), the Warwick Prize from the National Cancer Institute of Canada (2003), an honorary degree (DSc) from London University, UK (2009), and the European Society of Medical Oncology (ESMO) award (2012), the first non-European to receive this award. He chairs the scientific audit committee of the European Organisation for Research and Treatment of Cancer (EORTC) and is a member of the EORTC Board.
Dr. Tannock was appointed a Member of the Order of Canada in December 2014.
Christophe Le Tourneau has been appointed as a senior Medical Oncologist at the Institut Curie in November 2009. He is heading the Early Phase Clinical Trials Program as well as the Head and Neck Clinic. He is also involved in precision medicine clinical trials, having been the PI of the SHIVA trial. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of several phase I trials, as well as of clinical trials in Head and Neck oncology. He has published over 85 peer-reviewed papers in international journals.
In September 2011 Dr. Harold Varmus, Director of the US National Cancer Institute (NCI) appointed Dr. Trimble Director of the NCI’s new Center for Global Health. Between 1991 and 2011, Dr. Trimble was Head, Gynecologic Cancer Therapeutics and Quality of Cancer Care Therapeutics, Clinical Investigation Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, at the NCI. His duties were as scientific liaison with the Gynecologic Oncology Group and the American College of Surgeons Oncology Group, as well as oversight of issues involving the elderly, minorities, women’s health, international collaboration, cost, cancer health disparities, health-related quality of life and patient-reported outcomes in NCI-sponsored treatment trials. For his work at NCI he has received two Public Health Service Commendation Medals, 6 NIH Merit Awards, and the NCI Director’s Gold Star Award.
Following graduation from Harvard College and the Johns Hopkins University School of Medicine, Dr. Trimble trained in obstetrics and gynecology at the Vanderbilt University Medical Center. He earned a master’s degree in public health from the Johns Hopkins School of Hygiene and Public Health, and then completed a fellowship in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.
Jan Vijg, Ph.D., is Professor and Chairman of the Department of Genetics at the Albert Einstein College of Medicine in New York since 2008. Born in The Netherlands, he received his Ph.D. at the University of Leiden, The Netherlands, in 1987, and was previously an Associate Professor of Medicine at Harvard Medical School in Boston (1993-1999), a Professor of Physiology at the University of Texas Health Science Center in San Antonio, Texas (1999-2005), and a Professor at the Buck Institute for Research on Aging, Novato, California (2006-2008).
With his research team he was the first to develop transgenic mouse models for studying mutagenesis in vivo (in 1989) and used these models ever since in studying the possible relationship between damage to the genome, aging and cancer. He has published more than 300 scientific articles, is inventor or co-inventor on 8 patents and co-founded two biotechnology companies. He is the author of two books: Aging of the Genome: The Dual Role of DNA in Life and Death (Oxford University Press, New York, 2007) and The American Technological Challenge: Stagnation and Decline in the 21st Century (Algora Publishing, New York, 2007). Dr. Vijg's current work is in developing novel approaches in genomic medicine, with a focus on cancer and aging.